Antibody-Dependent Cell Cytotoxicity
"Antibody-Dependent Cell Cytotoxicity" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.
Concept/Terms
Antibody-Dependent Cell Cytotoxicity- Antibody-Dependent Cell Cytotoxicity
- Antibody Dependent Cell Cytotoxicity
- Cell Cytoxicity, Antibody-Dependent
- Antibody-Dependent Cell Cytoxicities
- Antibody-Dependent Cell Cytoxicity
- Cell Cytoxicities, Antibody-Dependent
- Cell Cytoxicity, Antibody Dependent
- Cytoxicities, Antibody-Dependent Cell
- Cytoxicity, Antibody-Dependent Cell
- ADCC
- Cytotoxicity, Antibody-Dependent Cell
- Antibody-Dependent Cell Cytotoxicities
- Cell Cytotoxicities, Antibody-Dependent
- Cell Cytotoxicity, Antibody-Dependent
- Cytotoxicities, Antibody-Dependent Cell
- Cytotoxicity, Antibody Dependent Cell
Below are MeSH descriptors whose meaning is more general than "Antibody-Dependent Cell Cytotoxicity".
Below are MeSH descriptors whose meaning is more specific than "Antibody-Dependent Cell Cytotoxicity".
This graph shows the total number of publications written about "Antibody-Dependent Cell Cytotoxicity" by people in Harvard Catalyst Profiles by year, and whether "Antibody-Dependent Cell Cytotoxicity" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 2 | 3 |
| 1995 | 1 | 1 | 2 |
| 1996 | 0 | 5 | 5 |
| 1997 | 1 | 2 | 3 |
| 1998 | 1 | 1 | 2 |
| 1999 | 2 | 1 | 3 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 5 | 5 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 3 | 1 | 4 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 3 | 4 |
| 2010 | 1 | 2 | 3 |
| 2011 | 2 | 3 | 5 |
| 2012 | 3 | 4 | 7 |
| 2013 | 1 | 4 | 5 |
| 2014 | 2 | 5 | 7 |
| 2015 | 6 | 6 | 12 |
| 2016 | 4 | 9 | 13 |
| 2017 | 3 | 5 | 8 |
| 2018 | 2 | 6 | 8 |
| 2019 | 6 | 5 | 11 |
| 2020 | 2 | 6 | 8 |
| 2021 | 4 | 10 | 14 |
| 2022 | 1 | 1 | 2 |
| 2023 | 1 | 3 | 4 |
Below are the most recent publications written about "Antibody-Dependent Cell Cytotoxicity" by people in Profiles.
-
ADCC-activating antibodies correlate with decreased risk of congenital human cytomegalovirus transmission. JCI Insight. 2023 07 10; 8(13).
-
ADCC's Improving Goal Concordant Care Initiative: Implementing Primary Palliative Care Principles. J Pain Symptom Manage. 2023 Aug; 66(2):e283-e297.
-
Targeting Tn-positive tumors with an afucosylated recombinant anti-Tn IgG. Sci Rep. 2023 03 28; 13(1):5027.
-
Indoline CD4-mimetic compounds mediate potent and broad HIV-1 inhibition and sensitization to antibody-dependent cellular cytotoxicity. Proc Natl Acad Sci U S A. 2023 03 28; 120(13):e2222073120.
-
HIV vaccine candidate efficacy in female macaques mediated by cAMP-dependent efferocytosis and V2-specific ADCC. Nat Commun. 2023 02 02; 14(1):575.
-
Cell-based reporter assays for measurements of antibody-mediated cellular cytotoxicity and phagocytosis against SARS-CoV-2 spike protein. J Virol Methods. 2022 09; 307:114564.
-
Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells. Cancer Immunol Immunother. 2022 Oct; 71(10):2497-2509.
-
ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection. PLoS Pathog. 2021 11; 17(11):e1010046.
-
Coordinated Fc-effector and neutralization functions in HIV-infected children define a window of opportunity for HIV vaccination. AIDS. 2021 10 01; 35(12):1895-1905.
-
Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma. Cancer Immunol Immunother. 2022 May; 71(5):1017-1031.